SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation

Table 1 Baseline demographic and clinical characteristics

Characteristic	D-SOX (n = 39)	DOS (n = 39)	P value
Age (years)
Median	50.5	50
Range	33–68	35–65
Sex
Male	18 (46 %)	20 (51 %)	0.65
Female	21 (54 %)	19 (49 %)
ECOG PS
1	27 (69 %)	27 (69 %)	1.00
2	12 (31 %)	12 (31 %)
Lauren classification
Diffuse type	27 (69 %)	26 (67 %)	0.81
Mixed type	12 (31 %)	13 (33 %)
Histologic type*
Undifferentiated	31 (79 %)	28 (72 %)	0.43
Differentiated	8 (21 %)	11 (28 %)
Previous chemotherapy
Yes	9 (23 %)	6 (15 %)	0.39
No	30 (77 %)	33 (85 %)
Amount of ascites**
Moderate	23 (59 %)	28 (72 %)	0.23
Massive	16 (41 %)	11 (28 %)
Burden of tumor***
PM only	15 (38 %)	10 (28 %)	0.23
Compound PM	24 (62 %)	29 (74 %)

Abbreviations: ECOG PS eastern Cooperative Oncology Group performance status, PM peritoneal metastasis; *Differentiated (well differentiated, moderately differentiated); undifferentiated, poorly differentiated adenocarcinoma (solid type, nonsolid type), signet ring cell carcinoma, and mucinous adenocarcinoma; ** Evaluated by computed tomography using a five-point method: Moderate, within the range of 1000–3000 ml; Massive, ascites beyond 3000 ml; *** PM only, peritoneal metastasis only, only abdominal implantation metastasis occurred; Compound PM, peritoneal metastasis combined with other metastases

ISSN: 1745-6215